TaperMD is a web-based clinical decision support system and clinical monitoring pathway that provides prescribers with tools and resources integrated with a proven methodology to manage, communicate and review patient medication plans with a focus on reducing the medication burden in a systematic and holistic manner.
TaperMD is a revolutionary approach to medication management developed through research at McMaster University in Canada to address the serious problems of polypharmacy and drug adverse events.
The team is run by experts in their field, Dr Dee Mangin fills the role of Chief Medical Officer for TaperMD. Dr Mangin is a family doctor originally from New Zealand, where she was a director of the Primary Care Research Unit at Otago University in Christchurch.
Dee moved to Canada in 2013 to become the David Braley Nancy Gordon Chair in Family Medicine and Research Director at McMaster University in Ontario, Canada. Her research is focussed on multi-morbidity, polypharmacy, and matching medical care to patients’ priorities and preferences.
An advocate for better independent information for patients and their doctors on drugs, Dee sits on the Section of Researchers’ Council with the College of Family Physicians of Canada (CFPC) and is a member of the Canadian Patient Safety Institute.
Dr David Healy is an internationally respected psychiatrist, psychopharmacologist, scientist, and author. A professor of Psychiatry at Bangor University in Wales, David is a former Secretary of the British Association for Psychopharmacology, and has authored more than 200 peer- reviewed articles and 20 books. David has been involved as an expert witness in homicide and suicide trials involving psychotropic drugs, and in bringing problems with these drugs to the attention of American and British regulators.
At IZY we assist TaperMD in an advisory capacity and feel very honoured to work alongside a company that has the aim of improving human wellbeing on a global scale. We are very excited for our collaborative future working together to help them achieve their vision.
Working with David and the team at Izy Capital allowed us to define our investment proposition and maximise shareholder value. The team adopt a professional and realistic approach to investor engagement and were a pleasure to have as a sounding
board on our strategic direction.
Ben Bennett, COO
Dave is a clear thinker and balances growth with reality. His experience in the private and public equity markets is rare to find. He is phenomenally well connected and has opened doors for us that wouldn’t have existed without his involvement
Phil Davies, CEO
Izy and more specifically David has enabled us to be laser focussed on delivery and customer segmentation. In a competitive market segment Dave has guided us to create a value proposition and outcomes orientated approach that is aligned with our mission of helping 500m to be more Mindful in their approach to life and others by 2025